Powered by

-Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin in Reduction of OsteoArthritis Knee Pain

Sep 29, 2020 - ENP Newswire

SAN DIEGO - Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento') released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.

Dr. David Leiman, MD, a board certified anesthesiologist, Clinical Assistant Professor of Surgery, University of Texa...